Clinical Trial Update: Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland [Phase 2]

View source ↗

Summary

Phase 2 study evaluating whether low-dose apalutamide can modulate PSA levels in men scheduled for prostatectomy for prostate cancer; results posted in 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Apalutamide (apalutamide)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Localized Prostate Carcinoma, Prostate Adenocarcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-08-29